matched control subjects. Patients and the control group were tested for the presence of increased factor VIII levels. FVIII activities were measured by the coagulometric assay (Diagnostica Stago, Paris, France). Patients were diagnosed with increased factor VIII levels if its value was > 2 SD of the mean age-adjusted level of control subjects (>200%). Fisher's exact test was used to compare the prevalence of a combination of factors between patients and control subjects. A P value < 0.05 was considered to be statistically significant.
When stroke occurred none of the patients had a condition predisposing to stroke, such as immobilization, sepsis, surgery, dehydration, trauma, or malignancy. Four patients (13.3%) and one control subject (3.03%) were diagnosed with increased factor VIII levels and this difference between groups was not statistically significant (P > 0.05) ( Table 1) .
Recently, new laboratory phenotypes such as high FVIII associated with an increased risk of venous thrombosis have been reported (3). Elevated FVIII is a strong risk factor for recurrence (5) . In patients with thrombosis, the high levels of FVIII persist over time and are not caused by acute phase reactions (1, 5, 6) .
In the general population, the prevalence of elevated FVIII levels ( 150 IU/dL) is 11%, whereas it has been found in 25 % of patients with a first episode of venous thrombosis (2) . In a pediatric thrombosis study of both venous and arterial disease, high levels of FVIII have been calculated to increase the risk of thrombosis approximately 11-fold (7) . Although no variations in the FVIII gene associated with high FVIII levels have been identified, FVIII levels tend to show a familial clustering (8) . Also, the mechanism between elevated FVIII and thrombosis remains unknown; it is partly mediated through an acquired activated protein C resistance (9) . In the present study an increased factor VIII level is not identified to be more common in stroke patients.
In addition to this, we found a case with ischemic stroke associated with a combination of heterozygous FVL mutation, a deficiency of antithrombin, and a high plasma level of FVIII (4) . There are other pediatric case reports with ischemic stroke and combined thrombophilia markers (10). The combination of thrombophilia markers increased the risk of stroke and the "thrombophilia burden" is definitely increased in children with ischemic stroke (11).
In conclusion, the relationship between ischemic stroke and increased FVIII levels is doubtful. Even if we could not find any significant statistical difference in FVIII level increase in children with ischemic stroke, in one patient with ischemic stroke we determined a high FVIII level with other thrombophilia factors. The increasing levels of FVIII together with other thrombophilia factors may be increasing the risk of ischemic stroke in childhood. Further studies must therefore be done in this subject. 
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